Angiogenesis inhibitors in the treatment of prostate cancer.

ABSTRACT:

Importance of the field

Prostate carcinoma is the most common non-cutaneous malignancy in U.S. men. The efficacy of docetaxel and prednisone in metastatic castrate-resistant prostate cancer (mCRPC) has been shown to improve overall survival; however, its effect is not durable, highlighting the need for new therapies.

Areas covered in this review

We will review the development of some of the leading compounds with direct and indirect antiangiogenic activity in prostate cancer including antibodies to VEGF and its receptors, small-molecule inhibitors of downstream signaling, immunomodulatory drugs with antiangiogenic activity, and compounds thought to directly inhibit or destroy vascular endothelial cells.

What the reader will gain

The reader will gain a basic understand

SUBMITTER: Kluetz PG 

PROVIDER: S-EPMC2811534 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature